A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

Loss in PKC Epsilon Causes Downregulation of MnSOD and BDNF Expression in Neurons of Alzheimer’s Disease Hippocampus

(2018) Abhik Sen et al.   JOURNAL OF ALZHEIMERS DISEASE

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials

(2017) Thomas J. Nelson et al.   JOURNAL OF ALZHEIMERS DISEASE

Towards universal therapeutics for memory disorders

(2015) Miao-Kun Sun et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Apolipoprotein E3 (ApoE3) but Not ApoE4 Protects against Synaptic Loss through Increased Expression of Protein Kinase Cϵ

(2012) Abhik Sen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

(2011) Martin Farlow et al.   BMC Neurology

PKC   Activation Prevents Synaptic Loss, A  Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice

(2011) J. Hongpaisan et al.   JOURNAL OF NEUROSCIENCE

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

Randomized Phase II Designs

(2009) L. Rubinstein et al.   CLINICAL CANCER RESEARCH

Reduction of β-Amyloid Levels by Novel Protein Kinase Cϵ Activators

(2009) Thomas J. Nelson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Postischemic PKC activation rescues retrograde and anterograde long-term memory

(2009) M.-K. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains

(2008) M.-K. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA